# US 8,772,269 B2 · Use of sulfonamide-including compounds in combination with angiogenesis inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,269 B2
- Document ID: US8772269B2
- Status: Granted
- Kind: B2
- Application number: 11/226,655
- Filed: 2005-09-13
- Published: 2006-06-22
- Granted: 2014-07-08
- Earliest claimed: 2004-09-13
- Assignees: Eisai R&D Management Co., Ltd.
- Applicants: Takashi Owa; Yoichi Ozawa; Taro Semba
- Inventors: Takashi Owa; Yoichi Ozawa; Taro Semba
- Web page: https://patentgrep.com/patent/US8772269B2

## CPC

- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/381: having five-membered rings
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/47: Quinolines; Isoquinolines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.

## Claims

### Claim 1

A pharmaceutical composition comprising a sulfonamide-including compound in combination with a VEGF receptor kinase inhibitor,
wherein the sulfonamide-including compound is N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide
or a pharmacologically acceptable salt thereof or a solvate thereof, and
wherein the VEGF receptor kinase inhibitor is 4-(3-chloro-4-(cyclopropyl-aminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmacologically acceptable salt thereof or a solvate thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the VEGF receptor kinase inhibitor is a methanesulfonate salt of 4-(3-chloro-4-(cyclopropylamino-carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

### Claim 3 (depends on 1, 2)

The pharmaceutical composition according to any one of claims 1 and 2, which is a pharmaceutical composition for cancer treatment.

### Claim 4 (depends on 1, 2)

The pharmaceutical composition according to any one of claims 1 and 2, which is a pharmaceutical composition for angiogenesis inhibition.

### Claim 5

A method for treating cancer and/or a method for inhibiting angiogenesis, which comprises administering a sulfonamide-including compound and a VEGF receptor kinase inhibitor to a patient,
wherein the sulfonamide-including compound is N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide, or a pharmacologically acceptable salt thereof or a solvate thereof, and
wherein the VEGF receptor kinase inhibitor is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmacologically acceptable salt thereof or a solvate thereof.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the VEGF receptor kinase inhibitor is a methanesulfonate salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.